Acorda Therapeutics Inc. (ACOR) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Comparison side by side

Both Acorda Therapeutics Inc. (NASDAQ:ACOR) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics Inc. 12 0.81 N/A -0.43 0.00
BiondVax Pharmaceuticals Ltd. 6 0.00 N/A -2.30 0.00

Table 1 demonstrates Acorda Therapeutics Inc. and BiondVax Pharmaceuticals Ltd.’s top-line revenue, earnings per share and valuation.


Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics Inc. 0.00% -1% -0.4%
BiondVax Pharmaceuticals Ltd. 0.00% 0% 0%

Analyst Ratings

The next table highlights the given recommendations and ratings for Acorda Therapeutics Inc. and BiondVax Pharmaceuticals Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acorda Therapeutics Inc. 0 1 1 2.50
BiondVax Pharmaceuticals Ltd. 0 0 0 0.00

$33 is Acorda Therapeutics Inc.’s consensus price target while its potential upside is 378.26%.

Insider and Institutional Ownership

Insiders held roughly 1.5% of Acorda Therapeutics Inc.’s shares. Competitively, BiondVax Pharmaceuticals Ltd. has 22.93% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acorda Therapeutics Inc. -4% -5.37% -26.85% -43.46% -54.52% -27.6%
BiondVax Pharmaceuticals Ltd. -2.13% -3.31% 10.72% 17.8% -6.28% 34.59%

For the past year Acorda Therapeutics Inc. had bearish trend while BiondVax Pharmaceuticals Ltd. had bullish trend.


On 5 of the 8 factors Acorda Therapeutics Inc. beats BiondVax Pharmaceuticals Ltd.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in ParkinsonÂ’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in ParkinsonÂ’s disease; SYN120, which is in Phase II clinical trial to treat ParkinsonÂ’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and WomenÂ’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.